These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31589081)

  • 1. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
    Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
    Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
    Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
    Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
    Joo YB; Sung YK; Shim JS; Kim JH; Lee EK; Lee HS; Bae SC
    Rheumatol Int; 2015 May; 35(5):879-86. PubMed ID: 25300729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States.
    Narayanan S; Wilson K; Ogelsby A; Juneau P; Durden E
    J Occup Environ Med; 2013 Nov; 55(11):1262-70. PubMed ID: 24202242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
    Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
    Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic burden of sarcoidosis in a commercially-insured population in the United States.
    Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
    J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.
    Slawsky KA; Fernandes AW; Fusfeld L; Manzi S; Goss TF
    Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1224-32. PubMed ID: 21584945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.
    McCormick N; Marra CA; Sadatsafavi M; Aviña-Zubieta JA
    Lupus; 2018 Jul; 27(8):1247-1258. PubMed ID: 29665755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
    Wu SS; Perry A; Tkacz J; Bryant G
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
    [No Abstract]   [Full Text] [Related]  

  • 17. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease.
    Karve S; Candrilli S; Kappelman MD; Tolleson-Rinehart S; Tennis P; Andrews E
    J Pediatr; 2012 Oct; 161(4):662-670.e2. PubMed ID: 22578787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
    He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
    Value Health Reg Issues; 2024 Sep; 43():101001. PubMed ID: 38850589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
    Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
    Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.